BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 26314962)

  • 1. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
    Jimbo M; Blanco FF; Huang YH; Telonis AG; Screnci BA; Cosma GL; Alexeev V; Gonye GE; Yeo CJ; Sawicki JA; Winter JM; Brody JR
    Oncotarget; 2015 Sep; 6(29):27312-31. PubMed ID: 26314962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HuR Contributes to TRAIL Resistance by Restricting Death Receptor 4 Expression in Pancreatic Cancer Cells.
    Romeo C; Weber MC; Zarei M; DeCicco D; Chand SN; Lobo AD; Winter JM; Sawicki JA; Sachs JN; Meisner-Kober N; Yeo CJ; Vadigepalli R; Tykocinski ML; Brody JR
    Mol Cancer Res; 2016 Jul; 14(7):599-611. PubMed ID: 27053682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
    Jakstaite A; Maziukiene A; Silkuniene G; Kmieliute K; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2015 Dec; 21(46):13004-19. PubMed ID: 26675757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Posttranscriptional Regulation of
    Chand SN; Zarei M; Schiewer MJ; Kamath AR; Romeo C; Lal S; Cozzitorto JA; Nevler A; Scolaro L; Londin E; Jiang W; Meisner-Kober N; Pishvaian MJ; Knudsen KE; Yeo CJ; Pascal JM; Winter JM; Brody JR
    Cancer Res; 2017 Sep; 77(18):5011-5025. PubMed ID: 28687616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human antigen R mediated post-transcriptional regulation of inhibitors of apoptosis proteins in pancreatic cancer.
    Lukosiute-Urboniene A; Jasukaitiene A; Silkuniene G; Barauskas V; Gulbinas A; Dambrauskas Z
    World J Gastroenterol; 2019 Jan; 25(2):205-219. PubMed ID: 30670910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.
    Pineda DM; Rittenhouse DW; Valley CC; Cozzitorto JA; Burkhart RA; Leiby B; Winter JM; Weber MC; Londin ER; Rigoutsos I; Yeo CJ; Gorospe M; Witkiewicz AK; Sachs JN; Brody JR
    Cancer Biol Ther; 2012 Aug; 13(10):946-55. PubMed ID: 22785201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
    Lal S; Burkhart RA; Beeharry N; Bhattacharjee V; Londin ER; Cozzitorto JA; Romeo C; Jimbo M; Norris ZA; Yeo CJ; Sawicki JA; Winter JM; Rigoutsos I; Yen TJ; Brody JR
    Cancer Res; 2014 Feb; 74(4):1128-40. PubMed ID: 24536047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells.
    Blanco FF; Jimbo M; Wulfkuhle J; Gallagher I; Deng J; Enyenihi L; Meisner-Kober N; Londin E; Rigoutsos I; Sawicki JA; Risbud MV; Witkiewicz AK; McCue PA; Jiang W; Rui H; Yeo CJ; Petricoin E; Winter JM; Brody JR
    Oncogene; 2016 May; 35(19):2529-41. PubMed ID: 26387536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F; Pineda DM; Jimbo M; Lal S; Burkhart RA; Moughan J; Winter KA; Abdelmohsen K; Gorospe M; Acosta Ade J; Lankapalli RH; Winter JM; Yeo CJ; Witkiewicz AK; Iacobuzio-Donahue CA; Laheru D; Brody JR
    Cancer Biol Ther; 2014 Jun; 15(6):688-98. PubMed ID: 24618665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.
    Huang YH; Peng W; Furuuchi N; Gerhart J; Rhodes K; Mukherjee N; Jimbo M; Gonye GE; Brody JR; Getts RC; Sawicki JA
    Cancer Res; 2016 Mar; 76(6):1549-59. PubMed ID: 26921342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
    Richards NG; Rittenhouse DW; Freydin B; Cozzitorto JA; Grenda D; Rui H; Gonye G; Kennedy EP; Yeo CJ; Brody JR; Witkiewicz AK
    Ann Surg; 2010 Sep; 252(3):499-505; discussion 505-6. PubMed ID: 20739850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
    Tatarian T; Jiang W; Leiby BE; Grigoli A; Jimbo M; Dabbish N; Neoptolemos JP; Greenhalf W; Costello E; Ghaneh P; Halloran C; Palmer D; Buchler M; Yeo CJ; Winter JM; Brody JR
    Ann Surg; 2018 Feb; 267(2):364-369. PubMed ID: 27893535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
    Zhou H; Telonis AG; Jing Y; Xia NL; Biederman L; Jimbo M; Blanco F; Londin E; Brody JR; Rigoutsos I
    Cell Death Dis; 2016 Jul; 7(7):e2294. PubMed ID: 27415424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated HuR in Pancreas Promotes a Pancreatitis-Like Inflammatory Microenvironment That Facilitates Tumor Development.
    Peng W; Furuuchi N; Aslanukova L; Huang YH; Brown SZ; Jiang W; Addya S; Vishwakarma V; Peters E; Brody JR; Dixon DA; Sawicki JA
    Mol Cell Biol; 2018 Feb; 38(3):. PubMed ID: 29133460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR Knockout of the HuR Gene Causes a Xenograft Lethal Phenotype.
    Lal S; Cheung EC; Zarei M; Preet R; Chand SN; Mambelli-Lisboa NC; Romeo C; Stout MC; Londin E; Goetz A; Lowder CY; Nevler A; Yeo CJ; Campbell PM; Winter JM; Dixon DA; Brody JR
    Mol Cancer Res; 2017 Jun; 15(6):696-707. PubMed ID: 28242812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of HuR inhibition by the small molecule MS-444 on colorectal cancer cell tumorigenesis.
    Blanco FF; Preet R; Aguado A; Vishwakarma V; Stevens LE; Vyas A; Padhye S; Xu L; Weir SJ; Anant S; Meisner-Kober N; Brody JR; Dixon DA
    Oncotarget; 2016 Nov; 7(45):74043-74058. PubMed ID: 27677075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
    Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
    Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding and targeting the disease-related RNA binding protein human antigen R (HuR).
    Schultz CW; Preet R; Dhir T; Dixon DA; Brody JR
    Wiley Interdiscip Rev RNA; 2020 May; 11(3):e1581. PubMed ID: 31970930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth
    Muralidharan R; Babu A; Amreddy N; Srivastava A; Chen A; Zhao YD; Kompella UB; Munshi A; Ramesh R
    Mol Cancer Ther; 2017 Aug; 16(8):1470-1486. PubMed ID: 28572169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer.
    Burkhart RA; Pineda DM; Chand SN; Romeo C; Londin ER; Karoly ED; Cozzitorto JA; Rigoutsos I; Yeo CJ; Brody JR; Winter JM
    RNA Biol; 2013 Aug; 10(8):1312-23. PubMed ID: 23807417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.